Daiichi Sankyo and Amplimmune have collaborated to develop AMP-110 therapeutic protein for the treatment of autoimmune diseases. The companies expect to commence Phase 1 study of the AMP-110 immune modulation therapy, which targets ...
Tags: Daiichi Sankyo, Amplimmune, therapeutic protein, autoimmune diseases